On December 2nd, at the “Future 20·2025 Annual Selection of Small and Mid-Cap Growth Enterprises among A-Share Listed Companies” held in Shanghai, Jiudian Pharmaceutical was awarded the title of "2025 A-Share Listed Company Growth Enterprise of the Year" jointly presented by China Business Network (CBN), Ernst & Young (China) and SIA Asset Management. The award recognized the company’s outstanding innovation capability, steady operating performance and remarkable growth potential. Ms. Zeng, Deputy General Manager and Board Secretary of Jiudian Pharmaceutical, attended the event and accepted the award on behalf of the company.

Solid Foundation Underpins Sustainable High-Growth

Jiudian Pharmaceutical has consolidated its development foundation through sustained high-intensity R&D investment and an integrated industrial layout. Over the past three years, the company’s R&D investment ratio has remained consistently above 9%, with R&D expenditure reaching 261 million yuan in 2024, significantly higher than the industry average. Meanwhile, by building an integrated industrial layout covering pharmaceutical preparations, active pharmaceutical ingredients (APIs) and pharmaceutical excipients, the company has achieved independent control over key raw materials and localized substitution of critical excipients. This not only ensures supply chain security, but also enhances cost control capability. By taking the lead in formulating a number of industry standards, Jiudian Pharmaceutical is working with the industry to move towards standardized and high-quality development.

Innovation-Driven Strategy Builds Core Engine for Growth

As a leading enterprise in China’s transdermal drug delivery sector, Jiudian Pharmaceutical has always regarded "innovative R&D" as the cornerstone of its growth. Following the development path of "breaking through key technologies – building technology platforms – creating product matrices", the company has established a full-chain innovation ecosystem covering drug R&D and preparation production. By overcoming core technologies such as transdermal drug screening, independent development of pressure-sensitive adhesives and control of transdermal drug penetration, the company has built four major technology platforms including gel patches, hot-melt patches, solvent-based adhesive patches and semi-solid preparations, forming a pattern of collaborative innovation across multiple technologies. At present, the company has built an external patch product matrix covering chemical drugs and proprietary Chinese medicines, with its market share ranking among the top in China. Its independently developed Class 1 new Chinese medicine has successfully filled the gap in the field of Chinese medicine patches, serving as a powerful testament to the company’s innovation strength.

Outstanding Value Earns High Recognition from Capital Market

Winning the "2025 A-Share Listed Company Growth Enterprise of the Year" award is not only an affirmation of Jiudian Pharmaceutical’s past development achievements, but also a high recognition of its potential for sustained growth in the future. Renowned for its objectivity, impartiality and rigor, the selection process went through five rounds of stringent screening, ensuring that all winning enterprises are genuine high-growth standouts verified by data analysis, model evaluation and expert endorsement. The independence of the selection guarantees the credibility and authority of the results. The high gold content of this award is widely recognized by the capital market, reflecting that the company has not only built a solid moat in its main business, but also demonstrated cyclical growth resilience through continuous R&D innovation and clear strategic layout.

Going forward, the company will continue to adhere to the innovation-driven development strategy, deepen its technological advantages in the transdermal drug delivery field, and rely on its complete industrial chain layout to continuously deliver innovative achievements with international competitiveness. Jiudian Pharmaceutical is committed to repaying investors’ trust through sustained high-quality growth, creating long-term value for shareholders and contributing more to the construction of Healthy China.